The Asian Scientist 100
Di Li
Institution
National Astronomical Observatories of the Chinese Academy of Sciences
Country
China
Field
Aerospace & Astronomy
Li received the Marcel Grossmann Award for his pioneering contributions in the field of fast radio bursts. Li is the first scientist in China to receive this prize for research conducted within China.
(Photo: The Paper)
AWARDS
- Marcel Grossmann Award
Related articles
Vietnam Concerned Over HIV Donor Funding Cuts
The Vietnamese government warns that multi-million dollar donor cutbacks could undermine progress in the country’s HIV/AIDS services.
Cipla Gets FDA Approval For Generic HIV Drug
Tentative approval for a generic HIV drug for use outside of the United States has been granted to Indian manufacturer Cipla.
MSF Treats First CMV Patients With Oral Drugs
Through a deal brokered with drug manufacturer Roche, CMV patients in Myanmar now need not endure painful injections directly into the eye.
7 Must-Read Stories In July 2014
A round-up of our top stories in July 2014; spanning ancient fossils to cosmic rays and the most high profile retraction in recent years.
India’s Spending Cuts Will Hurt Already Inadequate Health Services
A commentary published in The BMJ has warned that the recently announced health spending cuts will weaken India's public health system.
Hong Kong Doctors Use Microwaves To Treat Liver Cancer
A new type of FDA-approved high efficiency microwave coagulation system has now been tested in Asia by doctors from the University of Hong Kong Li Ka Shing Faculty of Medicine.
Bristol-Myers Squibb Awards Four Grants For Hepatitis Education
To mark World Hepatitis Day 2012, the Bristol-Myers Squibb Foundation has awarded four new grants focused on Hepatitis B and Hepatitis C research in China and India.
PerkinElmer Acquires Chinese Infectious Disease Diagnostics Company
PerkinElmer has acquired Shanghai Haoyuan Biotech to extend its reach into the growing Chinese nucleic acid-based blood screening market.
Cost Effective To Track Hepatitis B Carriers
A study has determined that monitoring inactive chronic hepatitis B carriers is a cost-effective strategy for managing the disease in China.